Fosamax (alendronate) slows bone loss by disabling the cells responsible for breaking down bone tissue. Your body constantly recycles bone in a process where old bone is removed and new bone is built. In osteoporosis, the removal side outpaces the building side, and bones gradually weaken. Fosamax tips the balance back by targeting the cells that do the removing.
How Fosamax Affects Bone Cells
Your skeleton is not static. Specialized cells called osteoclasts dissolve small patches of aging bone, while other cells called osteoblasts fill those patches with fresh bone. This cycle keeps your skeleton strong, but after menopause or with certain medical conditions, osteoclasts become overactive and remove bone faster than osteoblasts can replace it.
Fosamax belongs to a class of drugs called bisphosphonates. Once you swallow it, the drug travels through your bloodstream and binds tightly to bone surfaces, especially in areas where osteoclasts are actively working. When osteoclasts try to dissolve bone in those areas, they absorb the drug along with the bone minerals. Inside the osteoclast, Fosamax disrupts an enzyme the cell needs to maintain its internal structure. Without that enzyme functioning properly, the osteoclast loses its ability to attach to bone, shrinks, and eventually dies. The net result: less bone gets removed, and the bone-building cells have time to catch up.
What makes Fosamax unusual is how long it sticks around. Once embedded in bone, the drug has a half-life of roughly 10 years. That means it continues working at low levels long after you stop taking it, which is why doctors sometimes recommend planned breaks from treatment.
How Well It Reduces Fractures
The main reason anyone takes Fosamax is to avoid breaking a bone. A meta-analysis of randomized controlled trials found that alendronate reduces hip fracture risk by 55% in postmenopausal women with osteoporosis. That number improves further for people who take the medication consistently: women who stuck with their prescription had a 60% lower risk of hip fractures compared to those who didn’t.
There’s also a useful biomarker connection. Bone turnover can be measured through blood tests, and women whose bone turnover markers dropped by at least 30% during treatment had a 74% lower risk of hip fractures compared to those with smaller changes. This gives doctors a way to gauge whether the drug is doing its job before waiting years for a follow-up bone density scan.
Why the Dosing Instructions Are So Specific
Fosamax has notoriously strict dosing rules, and they exist for a good reason. Less than 1% of the drug you swallow actually makes it into your bloodstream. The oral bioavailability sits at roughly 0.6%, which means almost all of it passes through without being absorbed. Food, coffee, juice, milk, and mineral water reduce that already tiny absorption even further, potentially to zero.
To get the most out of each dose, you need to take it first thing in the morning on a completely empty stomach with a full glass (6 to 8 ounces) of plain water. Not mineral water, not sparkling water, not coffee. Plain tap or filtered water only. Then you wait at least 30 minutes before eating, drinking anything else, or taking any other medications, including vitamins and calcium supplements.
During that 30-minute window, you also need to stay upright. Sitting or standing keeps the tablet moving through your esophagus and into your stomach, which reduces the chance of irritation to the lining of your throat. Lying down allows the tablet or its residue to sit against the esophageal wall, which can cause inflammation or ulceration. This is the most common complaint people have with the drug, and following the posture rule carefully makes a significant difference.
Daily vs. Weekly Dosing
Fosamax comes in both daily and weekly formulations. For treating osteoporosis, the standard options are 10 mg daily or 70 mg once a week. For prevention (used in postmenopausal women who don’t yet have osteoporosis but are at risk), the doses are lower: 5 mg daily or 35 mg weekly. An oral liquid form is also available for people who have difficulty swallowing tablets.
Most people end up on the weekly schedule simply because it’s easier to manage. Research has also found that women taking the weekly dose were about 16% less likely to suffer hip fractures than those on the daily regimen, likely because weekly dosing is easier to stick with consistently over months and years.
Rare but Serious Risks
Two uncommon complications get the most attention with long-term Fosamax use. The first is osteonecrosis of the jaw, a condition where a section of jawbone loses its blood supply and begins to deteriorate. A large study of over 60,000 alendronate users found the rate of surgically treated jaw osteonecrosis was about 2.5 cases per 10,000 patient-years. That’s low, but the risk rises with longer use and is higher in people with conditions affecting the oral mucosa, such as poorly fitting dentures or recent dental surgery.
The second concern is atypical femur fractures. These are unusual breaks in the thighbone that can occur with very long-term bisphosphonate use, possibly because the drug suppresses normal bone remodeling so thoroughly that microdamage accumulates instead of being repaired. Both of these complications are part of the reason doctors now recommend periodic breaks from treatment rather than indefinite use.
Drug Holidays and How Long to Stay On It
Because Fosamax lingers in bone for years, planned treatment pauses (called drug holidays) are now standard practice. The length of treatment and the length of the break depend on your fracture risk.
- Mild fracture risk: 3 to 5 years of treatment, then stop until bone density drops significantly or a fracture occurs.
- Moderate fracture risk: 5 to 10 years of treatment, followed by a 3 to 5 year break.
- High fracture risk (history of fractures, steroid use, very low bone density): up to 10 years of treatment, with a shorter holiday of 1 to 2 years.
During a drug holiday, bone density is monitored periodically. If scans show meaningful bone loss or if you fracture a bone, treatment typically restarts. The drug’s decade-long half-life in bone means you retain some protective benefit even during the pause, though that residual effect gradually fades.